Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
Sexual Dysfunctions, Psychological
About this trial
This is an interventional treatment trial for Sexual Dysfunctions, Psychological
Eligibility Criteria
Inclusion Criteria: Women who are 18 years of age and older. Premenopausal women having regular menstrual periods who have HSDD (decreased sexual desire), generalized acquired type, according to DSM IV-TR criteria. Patient must meet minimum cut-off scores on questionnaires relating to sexual functioning and sexual distress. Patients must be willing to try to have sexual activity (e.g., any act involving direct genital stimulation) at least once monthly. Patients must be willing and able to use an electronic diary on a daily basis (e.g., have access to a working land line telephone for daily data transmissions). At the Baseline Visit, patients must have complied with eDiary use adequately. Patients must be in a stable, monogamous, heterosexual relationship that is secure and communicative, for at least 1 year prior to the Screen Visit. The partner is expected to be physically present at least 50% of each month. Patients must have used a medically acceptable method of contraception for at least 3 months before the Baseline Visit (Visit 2) and continue to use that medically acceptable method of contraception during the trial. In the investigators opinion, patients must be reliable, honest, compliant, and agree to co-operate with all trial evaluations as well as to be able to perform them. Patients must be able and willing to give meaningful, written informed consent prior to participation in the trial, in accordance with regulatory requirements. Patients must have sufficient understanding to communicate effectively with the investigator, and be willing to discuss their sexual functioning with the investigative staff. Patients must have a clinically acceptable Pap smear as read by a cytology facility (no evidence of malignancy or squamous intraepithelial lesions) within 6 months before the Screen Visit. A score of 15 or higher on the FSDS-R at the screen Visit. Exclusion Criteria: Patients who have taken any medication noted in the protocols List of Prohibited Medications within 30 days before screening. Patients whose sexual function was affected (enhanced or worsened) in the investigators opinion by any medication within 30 days before the Screen Visit and anytime prior to the Baseline Visit. Patients with a history of drug dependence or abuse within the past one year. Patients with a history of multiple severe reactions (i.e., allergic or oversensitivity to usual doses) to drugs that affect the brain. Patients with a history of participation in a trial of another investigational medication within one month prior to the Screen Visit, or participation in any previous clinical trial of flibanserin. Patients who meet accepted diagnostic criteria for sexual disorders that would interfere with improvement in HSDD (sexual aversion, substance-induced sexual problems, urge to live as a man, etc. Patients who indicate that their sexual partner has inadequately treated sexual problems that could interfere with the patients response to treatment. Patients who have entered the menopausal transition or menopause or have had a hysterectomy. Patients with findings at the Screen Visit of infection, inflammation, undue tenderness, or shrinkage (atrophy) of the female organs. Patients who are breast feeding or have breastfed within the last 6 months prior to the Baseline Visit. Patients who are pregnant or have been pregnant within the last 6 months prior to the Baseline Visit. Patients with a history of Major Depressive Disorder within 6 months prior the Screen Visit, a score indicating depression on a depression scale, a history of suicide attempt, or current suicidal ideation evident at the Screen or Baseline Visit. Patients with a history of any other psychiatric disorders that could impact sexual function, risks patients safety, or may impact compliance. Patients who have started psychotherapy
Sites / Locations
- 511.75.01015 Boehringer Ingelheim Investigational Site
- 511.75.01028 Boehringer Ingelheim Investigational Site
- 511.75.01051 Boehringer Ingelheim Investigational Site
- 511.75.01063 Boehringer Ingelheim Investigational Site
- 511.75.01017 Boehringer Ingelheim Investigational Site
- 511.75.01014 Boehringer Ingelheim Investigational Site
- 511.75.01042 Boehringer Ingelheim Investigational Site
- 511.75.01022 Boehringer Ingelheim Investigational Site
- 511.75.01005 Boehringer Ingelheim Investigational Site
- 511.75.01053 Boehringer Ingelheim Investigational Site
- 511.75.01045 Boehringer Ingelheim Investigational Site
- 511.75.01065 Boehringer Ingelheim Investigational Site
- 511.75.01003 Boehringer Ingelheim Investigational Site
- 511.75.01030 Boehringer Ingelheim Investigational Site
- 511.75.01066 Boehringer Ingelheim Investigational Site
- 511.75.01040 Boehringer Ingelheim Investigational Site
- 511.75.01001 Boehringer Ingelheim Investigational Site
- 511.75.01062 Boehringer Ingelheim Investigational Site
- 511.75.01032 Boehringer Ingelheim Investigational Site
- 511.75.01047 Boehringer Ingelheim Investigational Site
- 511.75.01073 Boehringer Ingelheim Investigational Site
- 511.75.01035 Boehringer Ingelheim Investigational Site
- 511.75.01010 Boehringer Ingelheim Investigational Site
- 511.75.01041 Boehringer Ingelheim Investigational Site
- 511.75.01033 Boehringer Ingelheim Investigational Site
- 511.75.01002 Boehringer Ingelheim Investigational Site
- 511.75.01006 Boehringer Ingelheim Investigational Site
- 511.75.01023 Boehringer Ingelheim Investigational Site
- 511.75.01031 Boehringer Ingelheim Investigational Site
- 511.75.01050 Boehringer Ingelheim Investigational Site
- 511.75.01043 Boehringer Ingelheim Investigational Site
- 511.75.01025 Boehringer Ingelheim Investigational Site
- 511.75.01024 Boehringer Ingelheim Investigational Site
- 511.75.01009 Boehringer Ingelheim Investigational Site
- 511.75.01060 Boehringer Ingelheim Investigational Site
- 511.75.01004 Boehringer Ingelheim Investigational Site
- 511.75.01037 Boehringer Ingelheim Investigational Site
- 511.75.01054 Boehringer Ingelheim Investigational Site
- 511.75.01069 Boehringer Ingelheim Investigational Site
- 511.75.01012 Boehringer Ingelheim Investigational Site
- 511.75.01071 Boehringer Ingelheim Investigational Site
- 511.75.01038 Boehringer Ingelheim Investigational Site
- 511.75.01048 Boehringer Ingelheim Investigational Site
- 511.75.01061 Boehringer Ingelheim Investigational Site
- 511.75.01020 Boehringer Ingelheim Investigational Site
- 511.75.01052 Boehringer Ingelheim Investigational Site
- 511.75.01059 Boehringer Ingelheim Investigational Site
- 511.75.01021 Boehringer Ingelheim Investigational Site
- 511.75.01018 Boehringer Ingelheim Investigational Site
- 511.75.01067 Boehringer Ingelheim Investigational Site
- 511.75.01070 Boehringer Ingelheim Investigational Site
- 511.75.01064 Boehringer Ingelheim Investigational Site
- 511.75.01049 Boehringer Ingelheim Investigational Site
- 511.75.01013 Boehringer Ingelheim Investigational Site
- 511.75.01027 Boehringer Ingelheim Investigational Site
- 511.75.01044 Boehringer Ingelheim Investigational Site
- 511.75.01011 Boehringer Ingelheim Investigational Site
- 511.75.01055 Boehringer Ingelheim Investigational Site
- 511.75.01068 Boehringer Ingelheim Investigational Site
- 511.75.01007 Boehringer Ingelheim Investigational Site
- 511.75.01057 Boehringer Ingelheim Investigational Site
- 511.75.01046 Boehringer Ingelheim Investigational Site
- 511.75.01019 Boehringer Ingelheim Investigational Site
- 511.75.01036 Boehringer Ingelheim Investigational Site
- 511.75.02008 Boehringer Ingelheim Investigational Site
- 511.75.02002 Boehringer Ingelheim Investigational Site
- 511.75.02004 Boehringer Ingelheim Investigational Site
- 511.75.02005 Boehringer Ingelheim Investigational Site
- 511.75.02010 Boehringer Ingelheim Investigational Site
- 511.75.02011 Boehringer Ingelheim Investigational Site
- 511.75.02001 Boehringer Ingelheim Investigational Site
- 511.75.02007 Boehringer Ingelheim Investigational Site
- 511.75.02009 Boehringer Ingelheim Investigational Site
- 511.75.02013 Boehringer Ingelheim Investigational Site
- 511.75.02003 Boehringer Ingelheim Investigational Site
- 511.75.02012 Boehringer Ingelheim Investigational Site
- 511.75.02014 Boehringer Ingelheim Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Placebo Comparator
flibanserin
flibanserin 50mg
flibanserin 100mg
placebo
flibanserin 25 mg b.i.d
flibanserin 50mg qhs/b.i.d
flibanserin 50mg b.i.d./100mg qhs
placebo comparator